Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients’ survival
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cancerous inhibitor of protein phosphatase 2A (CIP2A) drives cellular transformation. The objective of this study was to detect the potential effects of CIP2A in renal cell carcinomas (RCCs). METHODS: A total of 107 RCC patients were involved in the study. Cancerous inhibitor of protein phosphatase 2A expression was investigated by real-time PCR and immunohistochemistry. In vitro, we examined the expression of CIP2A and c-Myc and tested the migration and invasion capability of A498 and KRC/Y cells with scratch migration assay and Matrigel invasion assay after down-regulating CIP2A expression using siRNA. RESULTS: Cancerous inhibitor of protein phosphatase 2A was over-expressed in RCC tissues. Clear cell RCC showed an even higher-CIP2A expression level than papillary or chromophobe RCC did. The CIP2A immunostaining level was positively correlated with primary tumour stage, lymph node metastasis, distant metastasis, TNM stage and histological grade (all P<0.05). High-CIP2A expression implied poor survival for patients (P<0.05). Cancerous inhibitor of protein phosphatase 2A depletion by siRNA down-regulated c-Myc expression and attenuated the migration and invasion of RCC cells. CONCLUSION: Higher-CIP2A expression positively correlates with the aggressive phenotype of RCCs, and predicts poor prognosis for patients. Cancerous inhibitor of protein phosphatase 2A may be a novel target for prevention and treatment of RCC metastasis and recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIF-2α Promotes Hypoxic Cell Proliferation by Enhancing c-Myc Transcriptional Activity
Gordan, J. D., Bertout, J. A., Hu, C.-J., Diehl, J. A., & Simon, M. C. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.006 · Cited by 781
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677 · cited 4×
“Cancerous inhibitor of protein phosphatase 2A (CIP2A), a cellular protein phosphatase 2A (PP2A) inhibitor, promotes the stability of c-Myc protein by inducing c-Myc serine 62 (S62) phosphorylation and inhibiting its degradation mediated by PP2A (Junttila et al, 2007).”
BackgroundInfluentialKrishnamachary, B., Zagzag, D., Nagasawa, H., Rainey, K., Okuyama, H., Baek, J. H., & Semenza, G. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3719 · Cited by 415 · cited 1×
“It is well established that VHL mutation and subsequent HIF1/2 a dysregulation play a key part in the pathogenesis of clear cell RCC (Krieg et al, 2000; Krishnamachary et al, 2006); therefore, it may be interesting to probe the effects of these molecular events on CIP2A expression.”
BackgroundKrieg, M., Haas, R., Brauch, H., Acker, T., Flamme, I., & Plate, K. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203938 · Cited by 396 · cited 1×
“It is well established that VHL mutation and subsequent HIF1/2 a dysregulation play a key part in the pathogenesis of clear cell RCC (Krieg et al, 2000; Krishnamachary et al, 2006); therefore, it may be interesting to probe the effects of these molecular events on CIP2A expression.”
BackgroundCIP2A Is Associated with Human Breast Cancer Aggressivity
Côme, C., Laine, A., Chanrion, M., Edgren, H., Mattila, E., Liu, X., Jonkers, J., Ivaska, J., Isola, J., Darbon, J.-M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3283 · Cited by 221
MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer
Khanna, A., Böckelman, C., Hemmes, A., Junttila, M. R., Wiksten, J.-P., Lundin, M., Junnila, S., Murphy, D. J., Evan, G. I., Haglund, C., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp103 · Cited by 185
Lucas, C. M., Harris, R. J., Giannoudis, A., Copland, M., Slupsky, J. R., & Clark, R. E. (2011) · Blood · doi:10.1182/blood-2010-08-304477 · Cited by 138
Overexpression and Small Molecule-Triggered Downregulation of CIP2A in Lung Cancer
Ma, L., Wen, Z.-S., Liu, Z., Hu, Z., Ma, J., Chen, X.-Q., Liu, Y.-Q., Pu, J.-X., Xiao, W.-L., Sun, H.-D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020159 · Cited by 96
Increase in CIP2A expression is associated with doxorubicin resistance
Choi, Y. A., Park, J. S., Park, M. Y., Oh, K. S., Lee, M. S., Lim, J.-S., Kim, K. I., Kim, K.-Y., Kwon, J., Yoon, D. Y., et al. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.01.018 · Cited by 54
CIP2A increases self-renewal and is linked to Myc in neural progenitor cells
Kerosuo, L., Fox, H., Perälä, N., Ahlqvist, K., Suomalainen, A., Westermarck, J., Sariola, H., & Wartiovaara, K. (2010) · Differentiation · doi:10.1016/j.diff.2010.04.003 · Cited by 35
Cited by
CIP2A is a target of bortezomib in human triple negative breast cancer cells
Tseng, L.-M., Liu, C.-Y., Chang, K.-C., Chu, P.-Y., Shiau, C.-W., & Chen, K.-F. (2012) · Breast Cancer Research · doi:10.1186/bcr3175 · Cited by 122
“Higher CIP2A expression has been shown as a prognostic factor predicting survival in gastric cancer [29], non-small cell lung cancer [27,45], renal cell carcinoma [46], serous ovarian cancer [47] and early stage tongue cancer [47].”
The role of CIP2A in cancer: A review and update
Soofiyani, S. R., Hejazi, M. S., & Baradaran, B. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.146 · Cited by 72
CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis
Fang, Y., Li, Z., Wang, X., & Zhang, S. (2012) · Tumor Biology · doi:10.1007/s13277-012-0492-2 · Cited by 40
CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma
Xue, Y., Wu, G., Wang, X., Zou, X., Zhang, G., Xiao, R., Yuan, Y., Long, D., Yang, J., Wu, Y., et al. (2013) · Medical Oncology · doi:10.1007/s12032-012-0406-6 · Cited by 34
Liu, N., He, Q.-M., Chen, J.-W., Li, Y.-Q., Xu, Y.-F., Ren, X.-Y., Sun, Y., Mai, H.-Q., Shao, J.-Y., Jia, W.-H., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-111 · Cited by 26
Metadata
- Authors
- Ren, J., Li, W., Yan, L., Jiao, W., Tian, S., Li, D., Tang, Y., Gu, G., Liu, H., & Xu, Z.
- Venue
- British Journal of Cancer
- Published
- 2011-11-10
- Volume
- 105
- Issue
- 12
- Pages
- 1905-1911
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2091129821
- Cited by
- 58
- References
- 10
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.